Pfister et al. demonstrated through preclinical models of NASH-induced HCC that the increase of hepatic CD8+PD1+ T cells induced by immunotherapy impairs immune surveillance and did not lead to tumor regression [17]. The gene discussed is CD8A; the disease is neoplasm.